Diversify Wealth Management LLC Sells 1,413 Shares of Medpace Holdings, Inc. $MEDP

Diversify Wealth Management LLC reduced its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 22.0% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 5,016 shares of the company’s stock after selling 1,413 shares during the period. Diversify Wealth Management LLC’s holdings in Medpace were worth $2,656,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in MEDP. NewEdge Advisors LLC lifted its position in Medpace by 22.1% during the 1st quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock valued at $319,000 after purchasing an additional 190 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Medpace by 3.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock worth $24,929,000 after purchasing an additional 3,010 shares during the period. Geneos Wealth Management Inc. increased its stake in shares of Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after acquiring an additional 37 shares during the last quarter. Sivia Capital Partners LLC bought a new stake in Medpace in the second quarter valued at approximately $296,000. Finally, M&T Bank Corp raised its stake in Medpace by 3.4% during the 2nd quarter. M&T Bank Corp now owns 939 shares of the company’s stock worth $295,000 after buying an additional 31 shares during the period. 77.98% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Weiss Ratings upgraded shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday. BMO Capital Markets increased their target price on shares of Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a report on Friday, July 24th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $535.00 price objective on shares of Medpace in a report on Thursday, July 23rd. Mizuho lifted their target price on Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Finally, Barclays set a $600.00 target price on Medpace in a report on Thursday, July 23rd. Three research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $584.18.

Medpace Price Performance

Shares of MEDP stock opened at $581.95 on Friday. The company has a fifty day moving average price of $533.75 and a two-hundred day moving average price of $491.74. Medpace Holdings, Inc. has a one year low of $373.00 and a one year high of $677.90. The stock has a market cap of $16.24 billion, a P/E ratio of 34.11, a P/E/G ratio of 2.66 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. During the same period in the previous year, the business earned $3.10 EPS. Medpace’s revenue for the quarter was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, equities research analysts anticipate that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO August J. Troendle sold 17,610 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $605.11, for a total value of $10,655,987.10. Following the completion of the sale, the chief executive officer directly owned 615,802 shares of the company’s stock, valued at $372,627,948.22. This trade represents a 2.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, VP Susan E. Burwig sold 7,500 shares of the business’s stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $600.00, for a total value of $4,500,000.00. Following the transaction, the vice president directly owned 62,984 shares in the company, valued at $37,790,400. The trade was a 10.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 55,371 shares of company stock worth $30,878,030 over the last ninety days. 20.50% of the stock is currently owned by corporate insiders.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.